While I think SNUS may be a good short-term investment (1-2 years), I am worried about future competition: when Tocosol paclitaxel is finally approved, the market will probably include several epothilones--both natural and semisynthetic--that have an identical MOA, are as well tolerated, and are as easy to adminster.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.